Lycopodium Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Lycopodium heeft een totaal eigen vermogen van A$127.4M en een totale schuld van A$0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk A$217.0M en A$89.6M. De EBIT Lycopodium is A$56.1M waardoor de rentedekking -21 is. Het heeft contanten en kortetermijnbeleggingen van A$67.6M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

AU$0

Schuld

Rente dekkingsratio	-21x
Contant	AU$67.56m
Aandelen	AU$127.44m
Totaal verplichtingen	AU$89.60m
Totaal activa	AU$217.04m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( A$180.4M ) LYL } overtreffen de korte termijn passiva ( A$77.1M ).

Langlopende schulden: De kortetermijnactiva LYL ( A$180.4M ) overtreffen de langetermijnschulden ( A$12.5M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: LYL is schuldenvrij.

Schuld verminderen: LYL had 5 jaar geleden geen schulden.

Schuldendekking: LYL heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: LYL heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.

Lycopodium Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Lycopodium Limited (ASX:LYL) entered into a Heads of Agreement to acquire 60% stake in Saxum Ingenieria S.a.

Lycopodium Limited, Annual General Meeting, Nov 12, 2024

Upcoming dividend of AU$0.40 per share

Independent Non-Executive Director recently bought AU$98k worth of stock

Lycopodium Limited Approves A Fully Franked Final Dividend for the Six Months Ended June 30, 2024, Payable on 4 October 2024

Final dividend of AU$0.40 announced

Now 28% undervalued

Lycopodium Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Now 25% undervalued

Now 20% undervalued after recent price drop

Now 20% undervalued

Executive Director recently sold AU$17m worth of stock

Upcoming dividend of AU$0.37 per share

Now 20% undervalued

MD & Executive Director recently sold AU$643k worth of stock

First half dividend of AU$0.37 announced

First half 2024 earnings released: EPS: AU$0.75 (vs AU$0.50 in 1H 2023)

Lycopodium Limited to Report First Half, 2024 Results on Feb 21, 2024

Executive Director recently sold AU$162k worth of stock

Upcoming dividend of AU$0.45 per share at 8.9% yield

Lycopodium Limited Announces Franked Dividend for the Six Months Ended 30 June 2023, Payable on 6 October 2023

Lycopodium Limited, Annual General Meeting, Nov 14, 2023

Full year 2023 earnings released: EPS: AU$1.18 (vs AU$0.68 in FY 2022)

Lycopodium Limited to Report Fiscal Year 2023 Results on Aug 22, 2023

Non-Executive Director recently sold AU$1.0m worth of stock

Investor sentiment improves as stock rises 16%

Upcoming dividend of AU$0.36 per share at 9.0% yield

First half 2023 earnings released: EPS: AU$0.50 (vs AU$0.38 in 1H 2022)

Lycopodium Limited to Report First Half, 2023 Results on Feb 22, 2023

Less than half of directors are independent

Upcoming dividend of AU$0.36 per share

Executive Director recently sold AU$329k worth of stock

Full year 2022 earnings released: EPS: AU$0.68 (vs AU$0.36 in FY 2021)

Lycopodium Limited to Report Fiscal Year 2022 Final Results on Oct 11, 2022

Lycopodium Limited to Report Fiscal Year 2022 Results on Aug 24, 2022

Lycopodium Limited Appoints Louise Bower as Non-Executive Director

Lycopodium Limited Announces the Resignation of Robert Osmetti as Director

Now 23% undervalued after recent price drop

Non-Executive Director recently sold AU$450k worth of stock

Lycopodium Limited Updates Earnings Guidance for the Year Ending 30 June, 2022

Less than half of directors are independent

Lycopodium Limited Announces Resignation of Lawrence (Laurie) Marshall as Director

Now 21% undervalued

Upcoming dividend of AU$0.18 per share

Now 22% undervalued

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Lycopodium Limited Announces Dividend for the Six Months Ended December 31, 2021, Payable on April 7, 2022

Lycopodium Limited to Report First Half, 2022 Results on Feb 23, 2022

Investor sentiment improved over the past week

Upcoming dividend of AU$0.15 per share

Full year 2021 earnings released: EPS AU$0.36 (vs AU$0.30 in FY 2020)

Less than half of directors are independent

First half 2021 earnings released: EPS AU$0.15 (vs AU$0.23 in 1H 2020)

New 90-day high: AU$5.89

New 90-day high: AU$5.05

New 90-day high: AU$4.87

Lycopodium Limited Wins EP Contract for Sandfire's Motheo Contract

Market bids up stock over the past week

Lycopodium Limited Announces Appointment of Karl Cicanese as its Director

Non-Executive Director recently sold AU$390k worth of stock

Earnings released

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven